850072-66-1

Basic information

• Product Name: methyl 6-(hydroxymethyl)benzothiophene-2-carboxylate
• Synonyms: methyl 6-(hydroxymethyl)-1-benzothiophene-2-carboxylate; Methyl-6-(hydroxymethyl)-1-benzothiophen-2-carboxylat
• CAS NO: 850072-66-1
• Molecular Formula: C₁₁H₁₀O₃S
• Molecular Weight: 222.26
• Mol File: 850072-66-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 393°C at 760 mmHg
• Flash Point: 191.5°C
• Density: 1.349g/cm³
• Vapor Pressure: 7.03E-07mmHg at 25°C
• Refractive Index: 1.658
• CAS DataBase Reference: methyl 6-(hydroxymethyl)benzothiophene-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 6-(hydroxymethyl)benzothiophene-2-carboxylate(850072-66-1)
• EPA Substance Registry System: methyl 6-(hydroxymethyl)benzothiophene-2-carboxylate(850072-66-1)

Safety Data

• Hazardous Substances Data: 850072-66-1(Hazardous Substances Data)

Upstream product

• 850074-42-9 2-ethyl 6-methyl benzo[b]thiophene-2,6-dicarboxylate 
• 850074-43-0 benzo[b]thiophene-2,6-dicarboxylic acid 2-ethyl ester 
• 153813-69-5 methyl 4-formyl-3-nitrobenzoate 
• 1289162-67-9 4-(hydroxymethyl)-2-nitrobenzaldehyde 
• 2365-48-2 Methyl thioglycolate 
• 67-56-1 methanol 
• 850072-65-0 6-hydroxymethyl-benzo[b]thiophene-2-carboxylic acid ethyl ester 

Downstream Products

• 102636-02-2 6-hydroxymethyl-benzo[b]thiophene-2-carboxylic acid 

Relevant articles and documents

DIMERIC COMPOUNDS AS STING AGONISTS

The present disclosure relates to dimeric STING agonists of Formulae (I), (II), (III), (IV), (V), and (VI), and pharmaceutically acceptable salts thereof. The present disclosure also relates to methods of preparing the compounds and methods of using the c

BENZOTHIOPHENE DERIVATIVES

The present invention relates to a novel class of benzothiophene amide derivatives. The hydroxamic acid compounds can be used to treat cancer. The benzothiophene amide compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.